Reuters logo
BRIEF-FDA committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder
October 31, 2017 / 9:02 PM / 24 days ago

BRIEF-FDA committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder

Oct 31 (Reuters) - Indivior PLC

* FDA advisory committees recommend approval of Indivior’s RBP-6000 for the treatment of opioid use disorder

* Indivior PLC - ‍FDA has set a prescription drug user fee act (PDUFA) target action date of November 30, 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below